We hypothesised that BMP inhibition might recapitulate the anabolic effects of anti-sclerostin antibodies in myeloma bone disease in vivo, since: (a) osteocyte-secreted sclerostin is a major mediator of the osteogenesis block in myeloma;45 (b) anti-sclerostin antibodies ‘activate’ quiescent BLCs to become thicker, active and produce bone matrix in vivo5 and (c) both Acvr1 and Bmpr1a knockout in vivo decreased Sost and Dkk1 transcription32,39. The gene discussed is SOST; the disease is plasma cell myeloma.